vicriviroc maleate
Modify Date: 2024-01-02 12:04:01
vicriviroc maleate structure
|
Common Name | vicriviroc maleate | ||
|---|---|---|---|---|
| CAS Number | 599179-03-0 | Molecular Weight | 649.701 | |
| Density | N/A | Boiling Point | 608.1ºC at 760mmHg | |
| Molecular Formula | C32H42F3N5O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of vicriviroc maleateVicriviroc maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). |
| Name | Vicriviroc Maleate |
|---|---|
| Synonym | More Synonyms |
| Description | Vicriviroc maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). |
|---|---|
| Related Catalog | |
| Target |
CCR5:2.5 nM (Ki) HIV-1 (301657):1.8 nM (IC90, in PBMC cells) HIV-1 (ADA-M):2.8 nM (IC90, in PBMC cells) HIV-1 (JrFL):3.3 nM (IC90, in PBMC cells) HIV-1 (JV1083):4.9 nM (IC90, in PBMC cells) HIV-1 (RU 570):10 nM (IC90, in PBMC cells) |
| In Vitro | Vicriviroc (Sch-417690/Sch-D) is a potent, selective and oral bioavailable inhibitor of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 (JrFL), 2.8 (ADA-M), 1.8 (301657), 4.9 (JV1083) and 10 nM (RU 570). In addition, Vicriviroc shows a mean IC50 and IC90 of 0.45 nM and 4 nM for a panel of HIV isolates, and has weak activity against hERG activity (IC50, 5.8 μM)[1]. Vicriviroc inhibits chemotactic response to MIP-1α with IC50 values below 1 nM, and suppresses RANTES-induced signaling with a mean IC50 of 4.2 ± 1.3 nM. Vicriviroc potently suppresses all the viral isolates tested, with geometric mean EC50s of 0.04-2.3 nM and IC90s of 0.45-18 nM[2]. |
| In Vivo | Vicriviroc (10 mg/kg) has good oral availablity in rats and monkeys, with no acute CNS or GI effects in rats[1]. |
| Cell Assay | Ficoll-purified peripheral blood mononuclear cells (PBMCs) are stimulated in vitro with phytohemagglutinin (PHA) (5 μg/mL) and interleukin-2 (IL-2) (50 U/mL) for 3 to 7 days. The cells are resuspended at 4 × 106/mL in complete medium (RPMI, 10% fetal bovine serum [FBS], 50 U/mL IL-2), seeded into 96-well plates (2 × 105/well), incubated with an equal volume of culture medium containing compound (Vicriviroc) for 1 h at 37°C, and infected in triplicate with 25 to 100 50% tissue culture infectious doses (TCID50) per well of viral inoculum for 3 to 4 h. Cells are washed twice in phosphate-buffered saline (PBS) to remove residual virus and are cultured with compound for 4 to 6 days. HIV-1 replication is quantified by measurement of extracellular p24 antigen in the supernatants by enzyme-linked immunosorbent assay. The 50% effective concentrations (EC50s) and EC90s for each virus are determined using Graphpad PRISM software[2]. |
| References |
| Boiling Point | 608.1ºC at 760mmHg |
|---|---|
| Molecular Formula | C32H42F3N5O6 |
| Molecular Weight | 649.701 |
| Exact Mass | 649.308716 |
| PSA | 136.40000 |
| LogP | 4.02620 |
| Storage condition | 2-8℃ |
| VICRIVIROC MALEATE: SCH-D |
| vicriviroc Maleate salt |
| (4,6-Dimethylpyrimidin-5-yl){4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}methanone (2Z)-but-2-enedioate (1:1) |
| (4,6-Dimethyl-5-pyrimidinyl){4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl}methanone (2Z)-2-butenedioate (1:1) |
| Methanone, (4,6-dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]-, (2Z)-2-butenedioate (1:1) |
| vicriviroc maleate |
| SCH-D |
| Unii-ep3qg127N9 |
| Sch-417690 |
| Vicriviroc (maleate) |